重大公告
Clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study in the United States
Date of occurrence of the event: Nov 02, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head …
OBI Pharma Australia Pty Ltd announces the clearance of Adogloxad Simolenin (OBI-822) for a Phase III clinical study in Australia
Date of occurrence of the event: Oct 29, 2018 Company name: OBI Pharma Australia Pty Ltd Relationship to the Company (please enter “head office” or …
OBI received notice from patent attorney’s office that product patent for OBI-822 named “Compound and Compositions of Carbohydrate Vaccine and Uses Thereof” has been approved by Taiwan Intellectual Property Office
Date of occurrence of the event: Oct 01, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head …
Taiwan FDA clearance of Adagloxad Simolenin (OBI-822) for a Phase III clinical study
Date of occurrence of the event: Sept 28, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head …
Correction on previous announcement: “Clarification on the news article by Commercial Times” to “United Daily News”
Date of occurrence of the event: Sept 20, 2018 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head …